ShockWave Medical (SWAV) Stock

NEW YORK , May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.

Shockwave Medical (SWAV) reported quarterly earnings of $1.44 per share, exceeding the Zacks Consensus Estimate of $1.04 per share. This is an increase from earnings of $1.03 per share in the same quarter last year.

Shockwave Medical (SWAV) lacks the necessary elements for a potential earnings surpass in its upcoming report. Be ready with the important projections.

Shockwave Medical (SWAV) ended the most recent trading session at $328.99, showing a slight increase of 0.04% from the day before.

Shockwave Medical (SWAV) closed the most recent trading session at $329, marking a slight increase of 0.45% from the previous day's closing price.

Shockwave Medical (SWAV) has a strong track record of surprising earnings and is well positioned for another successful quarterly report.

Shockwave Medical (SWAV) reveals the real-world findings of the REDUCER-I study, which aims to gather extended results on the Shockwave Reducer, an innovative therapy for refractory angina.

Shockwave Medical Inc (NASDAQ:SWAV) is in the spotlight today, after blue-chip pharmaceutical giant Johnson & Johnson (JNJ) announced it would buy the company for $12.5 billion, boosting its portfolio of cardiovascular disease treatment devices.

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.